The Full Wiki

More info on Bivatuzumab

Bivatuzumab: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


(Redirected to Bivatuzumab mertansine article)

From Wikipedia, the free encyclopedia

Bivatuzumab mertansine ?
Monoclonal antibody
Type whole antibody
Source humanized (from mouse)
Target CD44 v6
ATC code none
Chemical data
Formula  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]


  1. ^ Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical cancer research : an official journal of the American Association for Cancer Research 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682. 

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44v6.[1] [2]

It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer"[3] ,(prior to 2002 it was described as targetting CD44v8[4])

It has been chemically linked to various radioisotopes for use in radiotherapy for, eg. inoperable recurrent or metastatic head and neck cancer.[1]

It has also been linked to a cytotoxic drug mertansine to form Bivatuzumab mertansine.



Got something to say? Make a comment.
Your name
Your email address